Breaking
Jimini Health raises $17M seed - total funding tops $25M Sage: AI support for the 167 hours a week you're not in session Every AI interaction stays under a licensed clinician's oversight Early data: ~36% drop in depression symptoms, half the in-person visits Backed by M13, Town Hall Ventures, Zetta & LionBird Founded by Immunai co-founder Luis Voloch Jimini Health raises $17M seed - total funding tops $25M Sage: AI support for the 167 hours a week you're not in session Every AI interaction stays under a licensed clinician's oversight Early data: ~36% drop in depression symptoms, half the in-person visits Backed by M13, Town Hall Ventures, Zetta & LionBird Founded by Immunai co-founder Luis Voloch
Company Profile · Behavioral Health · New York
Jimini Health logo mark

Jimini Health

Clinician-supervised AI for mental health care - an assistant named Sage that keeps a real therapist in the loop, always.

Founded 2023 $25M+ Raised ~23 Employees Product: Sage

A single glowing orb for a logo, sitting where a face would go. The company that wants AI in the therapy room insists the therapist never leaves it - so the mark stays quiet, and the humans stay in charge.


The Story

An AI therapist that reports to a human one

There is a familiar shape to AI pitches in healthcare: software walks in, the expensive human walks out, and a margin appears where a salary used to be. Jimini Health is selling the opposite trade, and doing it with a straight face.

The New York company builds behavioral health software around a product called Sage - an AI assistant that talks to patients before, during, and between their therapy sessions. Sage sends reminders, walks people through exercises, offers support at 2 a.m., and does the unglamorous work of keeping treatment going in the long stretches when no clinician is in the room. What Sage does not do is decide anything. Every conversation is visible to a clinical team, and the moment something looks serious, it escalates to a licensed human who owns the call.

That constraint - AI reach, human authority - is not a footnote. It is the whole product. Jimini's argument is that behavioral health has two stubborn problems, effectiveness and access, and that the market's current answer to both, the unsupervised consumer chatbot, is quietly making things worse. The company likes to cite an uncomfortable number: more than a million people a week reportedly discuss suicide with ChatGPT, a tool that was never built to carry that weight. When Character.AI and Google settled wrongful-death suits tied to teen suicides that followed AI conversations, the lesson Jimini took was not "AI can't help." It was "AI without a clinician is a liability, so build the clinician in."

"Jimini is building the clinical infrastructure this category has never had: real supervision, real clinicians, real oversight." Morgan Blumberg, Partner, M13

You can read that quote two ways. One is the standard investor cheer. The other is a slightly damning observation about everyone else: that a category racing to put chatbots in front of vulnerable people has mostly skipped the boring part - the supervision, the escalation paths, the licensed humans - because the boring part is hard and doesn't demo well. Jimini's bet is that the boring part is also the moat. Trust, in mental health, is not a garnish. It is the entire meal.

$25M+
Total Raised
~36%
Depression Symptom Drop*
½
The In-Person Sessions*
3
Co-Founders
What It Actually Does

Meet Sage

A therapist sees you for one hour a week. Sage is built for the other 167.

Between Sessions

Continuous Support

Sage checks in, sends reminders, and guides patients through evidence-based exercises like CBT practice - so the work doesn't stop when the session ends.

Always Visible

Clinician Oversight

Clinical teams can see every Sage interaction. Therapists keep decision-making authority over all care - the AI assists, it does not diagnose or decide.

Safety First

Escalation Built In

When a conversation signals risk, Sage escalates to a licensed clinician. The design assumes the hard moments will come and routes them to a human.

For Providers

Care Infrastructure

Jimini embeds Sage into behavioral health provider organizations, letting each therapist support more patients without lowering the standard of care.

Measured

Measurement-Based Care

The platform pairs evidence-based practice with continuous data, tracking progress so treatment can be adjusted on signal, not guesswork.

On Your Phone

Patient-Facing App

Sage reaches individuals directly - available on Google Play - extending care to people under clinical supervision, wherever they are.

*Early clinical figures reported by the company; outcomes described as on par with standard outpatient care.


The People

Who's building it

A founding team that has pointed AI at hard biology before - and came back to do it in mental health.

LV

Luis Voloch

Co-founder & CEO

Previously co-founded Immunai, an AI-driven cancer immunotherapy company valued at over $1 billion. Now aiming the same machine-learning discipline at the mental health access gap.

MJ

Mark Jacobstein

Co-founder & President

A veteran operator in healthcare and technology (ex-Guardant Health, Immunai), focused on making therapists "both more effective with their work and able to help more patients."

SS

Sahil Sud

Co-founder

Rounds out a founding team drawn from AI, biotech, and healthcare - the mix Jimini leans on to keep engineering and clinical judgment in the same room.

"This is a leap forward for all of behavioral health." Dr. Johannes Eichstaedt, Stanford
Follow The Money

$25 million, and a clear thesis

Two rounds, sixteen months apart, and a roster of investors betting that oversight beats automation.

Pre-Seed · Nov 2024$8M
Seed · Mar 2026$17M
Total Raised$25M+
Seed Round Investors

2026

M13 · Town Hall Ventures · LionBird · Zetta Venture Partners · OneMind

Pre-Seed Investors

2024

Zetta Venture Partners · LionBird · PsyMed Ventures · BoxGroup · Arkitekt Ventures · SCB

The Record

How it got here

2023

Founded in New York

Voloch, Jacobstein, and Sud start Jimini Health with a deliberately unfashionable premise: keep the clinician in the loop.

November 2024

Public launch, $8M pre-seed

Jimini emerges publicly and introduces Sage, its clinician-supervised AI therapist assistant, framed around "responsible AI."

March 2026

$17M seed round

Led by M13 and Town Hall Ventures, pushing total funding past $25M. Plans: expand provider partnerships and broaden clinical capabilities across care settings.

The Landscape

Where it sits

Jimini shares the digital behavioral-health field with names like Eleos Health, Limbic AI, and Headspace. But its sharpest contrast isn't a competitor with a term sheet - it's the free chatbot already sitting in millions of pockets, doing informal, unsupervised therapy at scale with no clinician anywhere near it.

That framing is convenient, but it's also the honest version of the market. The question Jimini is really testing is whether people, providers, and regulators will pay for guardrails when a plausible-sounding substitute is free. If the answer is yes, the clinician-in-the-loop model stops looking cautious and starts looking like the only defensible way to put AI near a person in crisis.

Jimini's platform helps "make therapists both more effective with their work and able to help more patients." Mark Jacobstein, President
Worth Knowing

Three quick things

The Name

The AI assistant is called Sage - and it's explicitly built to work the 167 hours a week you are not in a therapy session.

The Pedigree

CEO Luis Voloch's last company, Immunai, applied AI to cancer immunotherapy and reached a valuation north of $1 billion.

The Stakes

Jimini frames its safety pitch against a stark backdrop: over a million people a week reportedly discuss suicide with ChatGPT.

Pass It On

Share this profile